Chronic inactive gastritis and coccoid Helicobacter pylori in patients treated for gastroesophageal reflux disease or with H pylori eradication therapy

American Journal of Clinical Pathology

Volumn 118, Issue 5, 2002, Pages 719-726

  Goldstein, Neal S ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Dyspepsia; Gastritis; Helicobacter pylori; Immunohistochemistry; Inflammation; Pathology; Proton pump inhibitors

Indexed keywords

PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT; ENZYME INHIBITOR; PROTON PUMP;

ARTICLE; CHRONIC INACTIVE GASTRITIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DUODENUM ULCER; DYSPEPSIA; ERADICATION THERAPY; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GIEMSA STAIN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCORING SYSTEM; STOMACH BIOPSY; STOMACH ULCER; ADULT; AGED; CHRONIC DISEASE; CLASSIFICATION; DRUG ANTAGONISM; DRUG COMBINATION; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOGENICITY; PATHOLOGY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; ENZYME INHIBITORS; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED; PROTON PUMPS;

EID: 0036834374     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/LJ4D-E2LX-7UMR-YMTH     Document Type: Article

References (45)

1. Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H pylori density and distribution. Gastrointest Endosc. 1994;40:342-345.
2. Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol. 1994;25:221-226.
3. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis: the updated Sydney System: International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-1181.
4. el Zimaity HM, Graham DY, al Assi MT, et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol. 1996;27:35-41.
5. Dixon MF, Genta RM, Yardley JH, et al. Histological classification of gastritis and Helicobacter pylori infection: an agreement at last? the International Workshop on the Histopathology of Gastritis. Helicobacter. 1997;2(suppl 1):S17-S24.
6. el Zimaity HM, Segura AM, Genta RM, et al. Histologic assessment of Helicobacter pylori status after therapy: comparison of Giemsa, Diff-Quik, and Genta stains. Mod Pathol. 1998;11:288-291.
7. el Zimaity HM. Accurate diagnosis of Helicobacter pylori with biopsy. Gastroenterol Clin North Am. 2000;29:863-869.
8. Warren JR. Gastric pathology associated with Helicobacter pylori. Gastroenterol Clin North Am. 2000;29:705-751.
9. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90:1401-1406.
10. Logan RP, Walker MM, Misiewicz JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut. 1995;36:12-16.
11. Stolte M, Meining A, Schmitz JM, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1998;12:247-253.
12. Stolte M, Meining A, Koop H, et al. Eradication of Helicobacter pylori heals atrophic corpus gastritis caused by long-term treatment with omeprazole. Virchows Arch. 1999;434:91-94.
13. van der Wouden EJ, Thijs JC, van Zwet AA, et al. Reliability of biopsy-based diagnostic tests for Helicobacter pylori after treatment aimed at its eradication. Eur J Gastroenterol Hepatol. 1999;11:1255-1258.
14. Larkin CJ, Watson RGP, Sloan JM, et al. Distribution of atrophy in Helicobacter pylori-infected subjects taking proton pump inhibitors. Scand J Gastroenterol. 2000;35:578-582.
15. Sipponen P. Update on the pathologic approach to the diagnosis of gastritis, gastric atrophy, and Helicobacter pylori and its sequelae. J Clin Gastroenterol. 2001;32:196-202.
16. Oberhuber G, Puspok A, Dejaco C, et al. Minimal chronic inactive gastritis: indicator of pre-existing Helicobacter pylori gastritis? Pathol Res Pract. 1996;192:1016-1021.
17. Muller H, Rappel S, Wundisch T, et al. Healing of active, non-atrophic autoimmune gastritis by H pylori eradication. Digestion. 2001;64:30-39.
18. Plein K, Madisch A, Stolte M, et al. Short-term changes in Helicobacter pylori gastritis and bulbitis during and after 2 weeks of treatment with omeprazole and amoxicillin in duodenal ulcer patients. Z Gastroenterol. 2001;39:503-510.
19. Andersen LP, Dorland A, Karacan H, et al. Possible clinical importance of the transformation of Helicobacter pylori into coccoid forms. Scand J Gastroenterol. 2000;35:897-903.
20. Berry V, Jennings K, Woodnutt G. Bactericidal and morphological effects of amoxicillin on Helicobacter pylori. Antimicrob Agents Chemother. 1995;39:1859-1861.
21. Bode G, Mauch F, Malfertheiner P. The coccoid forms of Helicobacter pylori: criteria for their viability. Epidemiol Infect. 1993;111:483-490.
22. Catrenich CE, Makin KM. Characterization of the morphologic conversion of Helicobacter pylori from bacillary to coccoid forms. Scand J Gastroenterol Suppl. 1991;181:58-64.
23. Cellini L, Allocati N, Angelucci D, et al. Coccoid Helicobacter pylori not culturable in vitro reverts in mice. Microbiol Immunol. 1994;38:843-850.
24. Cellini L, Allocati N, Di Campli E, et al. Helicobacter pylori: a fickle germ. Microbiol Immunol. 1994;38:25-30.
25. Ikeda F, Yokota Y, Mine Y, et al. Activity of cefixime against Helicobacter pylori and affinities for the penicillin-binding proteins. Antimicrob Agents Chemother. 1990;34:2426-2428.
26. Mizoguchi H, Fujioka T, Kishi K, et al. Diversity in protein synthesis and viability of Helicobacter pylori coccoid forms in response to various stimuli. Infect Immun. 1998;66:5555-5560.
27. Cao J, Li ZQ, Borch K, et al. Detection of spiral and coccoid forms of Helicobacter pylori using a murine monoclonal antibody. Clin Chim Acta. 1997;267:183-196.
28. Monstein HJ, Jonasson J. Differential virulence-gene mRNA expression in coccoid forms of Helicobacter pylori. Biochem Biophys Res Commun. 2001;285:530-536.
29. Monstein HJ, de la Cour CD, Jonasson J. Probing 23S ribosomal RNA cleavage sites in coccoid Helicobacrer pylori. Helicobacter. 2001;6:100-109.
30. Ashton-Key M, Diss TC, Isaacson PG. Detection of Helicobacter pylori in gastric biopsy and resection specimens. J Clin Pathol. 1996;49:107-111.
31. Dickey W, Kenny BD, McConnell JB. Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. Aliment Pharmacol Ther. 1996;10:289-293.
32. Enomoto H, Watanabe H, Nishikura K, et al. Topographic distribution of Helicobacter pylori in the resected stomach. Eur J Gastroenterol Hepatol. 1998;10:473-478.
33. Eshun JK, Black DD, Casteel HB, et al. Comparison of immunohistochemistry and silver stain for the diagnosis of pediatric Helicobacter pylori infection in urease-negative gastric biopsies. Pediatr Dev Pathol. 2001;3:82-88.
34. Jonkers D, Houben P, Stobberingh E, et al. Ongoing gastric acid inhibition is a confounding factor in Helicobacter pylori diagnosis. Eur J Gastroenterol Hepatol. 1997;9:49-53.
35. Jonkers D, Houben G, de Bruine A, et al. Prevalence of gastric metaplasia in the duodenal bulb and distribution of Helicobacter pylori in the gastric mucosa: a clinical and histopathological study in 96 consecutive patients. Ital J Gastroenterol Hepatol. 1998;30:481-483.
36. Moayyedi P, Dixon ME, Any role left for invasive tests? histology in clinical practice. Gut. 1998;43(suppl 1):S51-S55.
37. Rotimi O, Cairns A, Gray S, et al. Histological identification of Helicobacter pylori: comparison of staining methods. J Clin Pathol. 2000;53:756-759.
38. Kyzekove J, Arlt J, Arkova M. Is there any relationship between functional dyspepsia and chronic gastritis associated with Helicobacter pylori infection? Hepatogastroenterology. 2001;48:594-602.
39. Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol. 2001;15:413-431.
40. Meuwissen SG, Craanen ME, Kuipers EJ. Gastric mucosal morphological consequences of acid suppression: a balanced view. Best Pract Res Clin Gastroenterol. 2001;15:497-510.
41. Rokkas T. Impact of H pylori infection on the management of dyspepsia. Dig Dis. 2001;19:123-126.
42. Kyzekova J, Mour J. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection: prospective randomized intervention study. Hepatogastroenterology. 1999;46:2048-2056.
43. Friedman LS. Helicobacter pylori and nonulcer dyspepsia. N Engl J Med. 1998;339:1928-1930.
44. McColl K, Murray L, El Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998;339:1869-1874.
45. Blum AL, Talley NJ, O'Morain C, et al, for the Omeprazole Plus Clarithromycin and Amoxicillin Effect One Year After Treatment (OCAY) Study Group. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998;339:1875-1881.